文献速递消化系统肿瘤

二线阿柏西普联合FOLFIRI方案治疗结直肠癌肝转移的RESECTION前瞻性法国队列研究切除结果

Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
PubMed 文献 · Eur J Cancer · 2024-10-22

该法国多中心前瞻性观察性队列纳入137例奥沙利铂治疗失败后的结直肠癌肝转移患者,接受阿柏西普联合FOLFIRI每2周一次治疗,R0/R1切除率为17%(肝局限病变者为21%),切除患者中55%达到Blazer评分主要病理缓解,且总生存和无进展生存均显著优于未切除患者。

要点

  • 阿柏西普联合FOLFIRI二线治疗结直肠癌肝转移的R0/R1切除率为17%,肝局限病变者为21%。
  • 切除患者中55%达到Blazer评分主要病理缓解,中位OS为34.8个月 vs 未切除者9.1个月(p<0.0001)。
  • ≥3级不良事件发生率为34%,主要为全身健康状况恶化和腹泻。

核心结论

  • 结果提示,奥沙利铂方案失败后使用阿柏西普联合FOLFIRI可使近20%的结直肠癌肝转移患者实现R0/R1切除,多数切除病例达到主要病理缓解。
  • 切除患者的中位OS较未切除患者延长超过3倍(34.8个月 vs 9.1个月)。

研究设计与样本

  • 法国多中心前瞻性观察性队列研究(NCT05178745)。
  • 纳入137例结直肠癌肝转移患者(单纯或为主,允许最多5个<2 cm肺结节),在既往奥沙利铂方案失败后由医生选择开始阿柏西普联合FOLFIRI每2周一次治疗。
  • 主要终点为R0/R1切除率,次要终点包括OS、PFS、影像学和病理学缓解及安全性。
  • 患者中位年龄65岁,RAS/BRAF突变率分别为57%和9%,入组于22家法国中心。
  • 肝转移中位数目4个,同时性转移占82%,双叶分布占71%,局限于肝脏者占54%。

主要发现

  • 总体R0/R1切除率为17%,肝局限病变患者为21%。
  • 切除患者中55%达到Blazer评分主要病理缓解。
  • 切除患者的中位OS为34.8个月 vs 未切除患者9.1个月(p<0.0001)。
  • 切除患者的中位PFS为11.4个月 vs 未切除患者4.9个月(p<0.0001)。
  • 术后并发症发生率为17%(均为Dindo-Clavien I-II级),无术后死亡;≥3级不良事件发生率为34%,主要为全身健康状况恶化和腹泻。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate R0/R1 resection rate in patients with colorectal liver metastases (CLM) treated with aflibercept plus FOLFIRI after failure of a prior oxaliplatin-based regimen in daily clinical practice. METHODS: This French, multicentre, prospective, observational cohort (NCT05178745) included patients with CLM (alone or predominant; up to 5 lung nodules <2 cm allowed) initiating aflibercept plus FOLFIRI every 2 weeks per physician choice. Primary endpoint was R0/R1 resection rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), radiological and pathological responses, and safety. RESULTS: A total of 137 patients (median age 65 years, RAS/BRAF mutant 57 %/9 %) were enrolled at 22 French sites. CLM (median 4) were synchronous in 82 %, bilobar in 71 % and located in liver only in 54 %. Overall, 17 % of patients had R0/R1 resection (21 % for patients with liver-only disease). A major pathological response per Blazer score was observed in 55 % of resected patients, along with significantly longer OS (median 34.8 vs 9.1 months, p < 0.0001) and PFS (median 11.4 vs 4.9 months, p < 0.0001) compared to non-resected patients. Post-operative complications occurred in 17 % of patients (all Dindo-Clavien grade I-II) and there was no post-operative deaths. Overall, 34 % had grade ≥ 3 adverse events, mainly general health deterioration and diarrhea. CONCLUSIONS: Results suggest that aflibercept plus FOLFIRI, after failure of a prior oxaliplatin-based regimen, allows R0/R1 resection of CLM in almost 20 % of patients with a major pathological response in most cases and a median OS prolonged by more than 3-fold versus non-resected patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tougeron D, Bibeau F, Chibaudel B, et al. Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort. Eur J Cancer. 2024. PMID: 39486163. doi:10.1016/j.ejca.2024.115082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。